New Long-Acting diabetes shot shows promise in first human test

NCT ID NCT06439056

Completed Disease control Sponsor: Nanexa AB Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early study tested a single injection of NEX-22A, a long-acting version of the diabetes drug liraglutide, in 12 adults with type 2 diabetes. The main goal was to see how the drug moves through the body and if it is safe. Participants were on stable metformin therapy and received one dose. Results will help decide if further testing is warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NEX-22A (a long-acting form of liraglutide)
What this could lead to: If successful, this could lead to a once-weekly or less frequent injection for managing type 2 diabetes, improving convenience for patients.
What could go wrong: This is a very early Phase 1 study with only 12 participants, so it is too small to prove effectiveness or safety. The drug may not work as hoped or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

Profil

Neuss, 41460, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.